Can scans tell who needs surgery after liver tumor shrinks?
NCT ID NCT07581769
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks back at 500 people with liver cancer that could not be removed at first. After a mix of treatments (TACE, lenvatinib, and an immunotherapy drug), their tumors shrank enough to consider surgery. Researchers want to see if using scans and patient data can help decide who should have surgery and who should keep taking medicine for better long-term results.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DOWNSTAGING are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiiated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, 510080, China
-
Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong, 510280, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a 'No-Touch' microwave technique match surgery for liver tumors?
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- Which nerve block gets you breathing easier after liver surgery?
- Can a Triple-Drug combo outsmart a rare and aggressive cancer?
- AI-Powered surveillance may outsmart liver cancer recurrence
- Blood markers may forecast liver cancer treatment success